Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
Mehran Makvandi, Austin R. Pantel, Lauren E. Schwartz, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 5, pp. 2116-2126
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang, M Kellis, Weihua Li, et al.
Journal of Cellular and Molecular Medicine (2019) Vol. 23, Iss. 4, pp. 2303-2313
Open Access | Times Cited: 146
Advances in PET imaging of cancer
Johannes Schwenck, Dominik Sonanini, Jonathan Cotton, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 7, pp. 474-490
Closed Access | Times Cited: 108
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
Mirjam Gerwing, Ken Herrmann, Anne Helfen, et al.
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 7, pp. 442-458
Closed Access | Times Cited: 118
The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
Marco Gatti, Ralph Imhof, Qingyao Huang, et al.
Cell Reports (2020) Vol. 32, Iss. 5, pp. 107985-107985
Open Access | Times Cited: 95
PET Imaging of PARP Expression Using 18F-Olaparib
Thomas C. Wilson, Mary‐Ann E. Xavier, James C. Knight, et al.
Journal of Nuclear Medicine (2018) Vol. 60, Iss. 4, pp. 504-510
Open Access | Times Cited: 86
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
Stephen A. Jannetti, Brian M. Zeglis, Michael R. Zalutsky, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 76
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
Negesse Mekonnen, Hobin Yang, Young Kee Shin
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 58
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer
Xiaoxiang Sun, Huanyin Tang, Yu Chen, et al.
Nature Cancer (2023) Vol. 4, Iss. 5, pp. 716-733
Closed Access | Times Cited: 29
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 12
Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review
Tasnim Khessib, Priyanka Jha, Guido Davidzon, et al.
Seminars in Nuclear Medicine (2024) Vol. 54, Iss. 2, pp. 270-292
Closed Access | Times Cited: 9
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 64
Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein
Émilie Bayart, A. Flacco, Olivier Delmas, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 61
PARP Inhibitors in Cancer Diagnosis and Therapy
Chung Ying Chan, Kel Vin Tan, Bart Cornelissen
Clinical Cancer Research (2020) Vol. 27, Iss. 6, pp. 1585-1594
Open Access | Times Cited: 61
The evolving landscape of predictive biomarkers of response to PARP inhibitors
Anish Thomas, Junko Murai, Yves Pommier
Journal of Clinical Investigation (2018) Vol. 128, Iss. 5, pp. 1727-1730
Open Access | Times Cited: 60
Homologous recombination deficiency real-time clinical assays, ready or not?
Katherine C. Fuh, Mary M. Mullen, Barbara Blachut, et al.
Gynecologic Oncology (2020) Vol. 159, Iss. 3, pp. 877-886
Closed Access | Times Cited: 57
Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer
Heiko Schöder, Paula Demétrio De Souza França, Reiko Nakajima, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 13, pp. 3110-3116
Open Access | Times Cited: 56
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Iris K. Lee, Estela Noguera-Ortega, Zebin Xiao, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 24, pp. 5330-5342
Open Access | Times Cited: 34
[123I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
Chung Ying Chan, Zijun Chen, Florian Guibbal, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 12, pp. 1965-1971
Open Access | Times Cited: 17
Fluorine-18: A radionuclide with diverse range of radiochemistry and synthesis strategies for target based PET diagnosis
Sridhar Goud Nerella, Raman Kumar Joshi, Rose Dawn Bharath, et al.
European Journal of Medicinal Chemistry (2019) Vol. 187, pp. 111979-111979
Closed Access | Times Cited: 46
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Yu‐Yi Chu, Clinton Yam, Mei‐Kuang Chen, et al.
PubMed (2020) Vol. 10, Iss. 2, pp. 648-661
Closed Access | Times Cited: 42
Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications
Mehdi Azizi, Hassan Dianat‐Moghadam, Roya Salehi, et al.
Advanced Functional Materials (2020) Vol. 30, Iss. 19
Open Access | Times Cited: 41
Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA
Michele Salemi, Maria P. Mogavero, Giuseppe Lanza, et al.
Cells (2022) Vol. 11, Iss. 12, pp. 1930-1930
Open Access | Times Cited: 26
CRISPR-cas9 genome editing delivery systems for targeted cancer therapy
Asma Ghaemi, Elnaz Bagheri, Khalil Abnous, et al.
Life Sciences (2020) Vol. 267, pp. 118969-118969
Closed Access | Times Cited: 39
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
Jacob J. Adashek, Rohit Jain, Jingsong Zhang
Cells (2019) Vol. 8, Iss. 8, pp. 860-860
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top